By Kennedy Nalyanya
YOKOHAMA, JAPAN — In a bold move towards achieving health security and reducing its heavy reliance on foreign aid, Kenya has announced ambitious plans to begin clinical trials for its first locally manufactured vaccines by 2027. The initiative, led by the state-owned Kenya BioVax Institute, is a cornerstone of the country's long-term health strategy and a significant topic of discussion on the global stage, including at the recent Ninth Tokyo International Conference on African Development (TICAD9).
The plan is a direct response to a critical vulnerability: over 80% of Kenya’s annual vaccine budget is currently funded by external donors. With organizations like Gavi expected to gradually reduce their support as Kenya's economic status changes, local production is not just a goal but a strategic necessity. The Kenya BioVax Institute is targeting key childhood diseases like pneumonia and typhoid for its initial round of trials, with a broader vision to produce a range of therapeutics and immunizations.
This project has received a major vote of confidence from the World Bank, which has committed a significant funding package of approximately $62 million (about Ksh 8 billion) to support the establishment of the manufacturing facility in Nairobi. This "fill and finish" factory will initially focus on packaging imported vaccines before transitioning to full-scale local production. The facility is expected to bolster Kenya's resilience against future health crises, much like the one witnessed during the COVID-19 pandemic.
Discussions on this vital initiative have been a key part of the Kenyan delegation's agenda at TICAD9 in Yokohama, Japan. The conference, a major platform for cooperation between Japan and African nations, provided an ideal setting to highlight Kenya’s progress. Public Health Principal Secretary Mary Muthoni has been a prominent figure in these high-level talks, advocating for co-investment and technology transfer. The project is a prime example of the deepening bilateral ties between Kenya and Japan, with a shared focus on strengthening health systems and building a robust framework for health security.
By developing its own vaccine manufacturing capacity, Kenya is not only safeguarding its own public health but also positioning itself as a key player in the regional health supply chain. The plan aligns with the African Union's New Public Health Order, which calls for increased local production to correct the continent’s current imbalance of importing up to 98% of its vaccine supply. Kenya’s journey toward medical independence is a powerful statement for self-reliance and regional leadership.
Add comment
Comments